US and Israeli researchers join forces by applying nanotechnology to cancer research10-01-2017
Each team was awarded $600,000 for two years.
American and Israeli research teams are preparing to explore treatments for cancer using science and engineering at the molecular level, commonly known as nanotechnology.
Researchers at the Hebrew University of Jerusalem and the Centre for Transformative Nanomedicine of Cleveland Clinic in Ohio have been awarded $1.2 million for collaboration at the two institutions. The two teams from Cleveland and Jerusalem will attempt to establish whether tiny nanoparticles can more effectively deliver treatments to brain and breast cancer and lead toward potential cures.
The family of Victor Cohn, a Cleveland real estate developer, donated $2m to kick off a five-year fund-raising effort that seeks a minimum of $15m. The debut grants concur with the centre’s one year anniversary.
Team members will also tap the resources of their respective institutions in Jerusalem and Cleveland. The grants are the first awards of the virtual centre, which combines the expertise of the department of biomedical engineering at Cleveland Clinic’s Lerner Research Institute and Hebrew University, which is one of the world’s foremost centres in nanotechnology. Cleveland Clinic is ranked the No. 2 hospital in America by US News & World Report.
One team will focus on the microbiome – the ecological community of microorganisms that share our body space – as scientists suspect there is a connection between gut bacteria imbalances and breast cancer. Researchers will try to determine whether they can stunt tumours and avoid the harmful side effects of traditional cancer treatments by using nanotechnology to deliver antibiotics directly to the bacterial community in breast cancer.
This team includes Hebrew University’s Dr. Arieh Moussaieff and Prof. Yechezkel Barenholz and Cleveland Clinic’s Dr. Stephen Grobmyer and Dr. Charis Eng.
A second team will seek to harness nanotechnology and stem cell therapies to treat glioblastoma, the most common and aggressive form of brain cancer. Researchers plan to use microchips to deliver treatments to lab-generated tumours, testing whether the procedure is safe and effective for people. If successful, such approaches could lead to new ways of addressing Alzheimer’s and Parkinson’s diseases. This team will be led by Dr. Jeremy Rich of Cleveland Clinic and Dr. Yaakov Nahmias of the Hebrew University.
Dr. D. Geoffrey Vince, chairman of biomedical engineering at the Lerner Research Institute, said both projects hold out the promise of finding more effective and inexpensive means of diagnosing and treating cancer and other complex diseases. He credits the collaboration with leveraging the assets of two world class science hubs to create better medicine.
“It’s hard to find two groups further apart geographically, but the collaboration is working extremely well,” said Vince, noting that the researchers communicate frequently by email and video conferencing and plan to meet in Cleveland this spring.
“It gives us a chance to address very important clinical questions using technology and approaches a world away. It’s a true symbiotic relationship. We can help them and they can help us.”
Vince leads the centre’s scientific efforts in Cleveland.
His counterpart in Israel is Prof. Simon Benita, the former head of the Hebrew University’s School of Pharmacy.
“We have embarked on a very fruitful scientific collaboration between two great institutions with complementary skills, bridging the gap from the bench to bedside for the benefit of patients suffering from severe diseases, particularly cancer, vascular and neurological disorders,” Benita said.
“Our Cleveland Clinic and Hebrew University scientists, who have met several times over the last two years, are excited by and enthusiastic about the potential to resolve challenging medical issues, and help patients, by combining their synergic skills,” he said.
Cohn called the venture “a great opportunity to foster collaboration with a leading hospital in the United States and the top Israeli university that has an international reputation for drug development.”
Lord Pannick, QC, at Blackstone Chambers, acted for the lead claimant Gina Miller in the historic 11-justice Supreme Court case.09-02-2017
Hebrew University Truman Institute together with Scholas Occurrentes Educational Organization established by Pope Francis, are developing a conference and a programme on Culture of Encounter through Education in Jerusalem08-02-2017
Hebrew University researchers are part of an international team that identified the chemical compounds and the functional genes that give a tomato its great taste05-02-2017
Prof. Liebes, from the Department of Jewish Thought, awarded for his work in Kaballah and Jewish myth05-02-2017
Discovery of the Dipole Repeller confirms that both attraction and repulsion are at play in our extragalactic neighbourhood30-01-2017
Hebrew University Researchers provide new insight into the brain mechanisms underlying a condition that causes reading and writing difficulties25-01-2017
New fragments of the Dead Sea Scrolls have been uncovered by Archaeologists working on a salvage excavation in the Cave of Skulls by the Dead Sea in Israel.10-01-2017
American and Israeli research teams are preparing to explore treatments for cancer using science and engineering at the molecular level, commonly known as nanotechnology.10-01-2017
Bacteriophages (phages) are probably the most abundant entities in nature, often exceeding bacterial densities by an order of magnitude.10-01-2017
Scientists present first direct evidence that human neocortical neurons have unique membrane properties that enhance signal processing04-01-2017
States can no longer legislate solely within their own boundaries; project aims address war, crime and privacy in cyberspace04-01-2017